KD Logo

Tourmaline Bio Inc (TRML) Becoming More Attractive for Investors

Tourmaline Bio Inc’s filing revealed that its CEO Kulkarni Sandeep Chidambar acquired Company’s shares for reported $26418.0 on Aug 21 ’24. In the deal valued at $14.85 per share,1,779 shares were bought. As a result of this transaction, Kulkarni Sandeep Chidambar now holds 7,000 shares worth roughly $0.12 million.

Then, Kulkarni Sandeep Chidambar bought 5,221 shares, generating $71,998 in total proceeds. Upon buying the shares at $13.79, the CEO now owns 5,221 shares.

BMO Capital Markets initiated its Tourmaline Bio Inc [TRML] rating to an Outperform in a research note published on December 06, 2024; the price target was $50. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in mid November has reiterated a ‘”a Buy”‘ rating for it. Jefferies began covering TRML with “Buy” recommendation on December 15, 2023.

Price Performance Review of TRML

On Tuesday, Tourmaline Bio Inc [NASDAQ:TRML] saw its stock jump 6.37% to $16.53. Over the last five days, the stock has gained 0.18%. Tourmaline Bio Inc shares have fallen nearly -18.49% since the year began. Nevertheless, the stocks have fallen -51.68% over the past one year. While a 52-week high of $48.31 was reached on 01/07/25, a 52-week low of $12.12 was recorded on 02/04/25. SMA at 50 days reached $20.89, while 200 days put it at $19.11.

Levels Of Support And Resistance For TRML Stock

The 24-hour chart illustrates a support level at 15.64, which if violated will result in even more drops to 14.76. On the upside, there is a resistance level at 16.99. A further resistance level may holdings at 17.46. The Relative Strength Index (RSI) on the 14-day chart is 34.94, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.99, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 66.41%. Stochastics %K at 12.15% indicates the stock is a buying.

How much short interest is there in Tourmaline Bio Inc?

A steep rise in short interest was recorded in Tourmaline Bio Inc stocks on 2025-01-15, growing by 0.68 million shares to a total of 2.33 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 1.64 million shares. There was a rise of 29.4%, which implies that there is a positive sentiment for the stock.

The most recent change occurred on November 17, 2023 when Truist began covering the stock and recommended ‘”a Buy”‘ rating along with a $43 price target.

Most Popular